COST-EFFECTIVENESS OF IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN ENGLAND

被引：0
|
作者：
Hassan, F. [1 ]
Peng, S. [2 ]
Dorman, E. [2 ]
Sorensen, S. [2 ]
Thompson, G. [1 ]
Lee, J. [1 ]
机构：
[1] Janssen UK, High Wycombe, Bucks, England
[2] Evidera, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.246
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN163
引用
收藏
页码：A441 / A441
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF OFATUMUMAB FOR MAINTENANCE IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
    Davies, A.
    Zou, D.
    Hurry, M.
    Bal, V.
    HAEMATOLOGICA, 2016, 101 : 146 - 146
  • [32] Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib
    Jones, Jeffrey
    Choi, Michael Y.
    Mato, Anthony R.
    Furman, Richard R.
    Davids, Matthew S.
    Heffner, Leonard T.
    Cheson, Bruce D.
    Lamanna, Nicole
    Barr, Paul M.
    Eradat, Herbert
    Halwani, Ahmad
    Chyla, Brenda
    Zhu, Ming
    Verdugo, Maria
    Humerickhouse, Rod A.
    Potluri, Jalaja
    Wierda, William G.
    Coutre, Steven E.
    BLOOD, 2016, 128 (22)
  • [33] Cost-Effectiveness Comparison between Ibrutinib, Chemotherapy, and Chemoimmunotherapy in Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
    Nabhan, Chadi
    Nero, Damion
    Lee, Choo Hyung
    Kish, Jonathan K.
    Mato, Anthony R.
    BLOOD, 2018, 132
  • [34] Australian data on the utilisation and duration on treatment of ibrutinib with a proton pump inhibitor in patients with relapsed or refractory chronic lymphocytic leukaemia
    Salvaris, Ross
    Mulligan, Stephen
    Puig, Andrea
    Mcgeachie, Marija
    Opat, Stephen
    INTERNAL MEDICINE JOURNAL, 2023, 53 (11) : 2115 - 2118
  • [35] Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
    Michaela Barbier
    Nicholas Durno
    Craig Bennison
    Mathias Örtli
    Christian Knapp
    Matthias Schwenkglenks
    The European Journal of Health Economics, 2022, 23 : 837 - 846
  • [36] Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
    Barbier, Michaela
    Durno, Nicholas
    Bennison, Craig
    Ortli, Mathias
    Knapp, Christian
    Schwenkglenks, Matthias
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2022, 23 (05): : 837 - 846
  • [37] PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (R/R CLL) INELIGIBLE FOR CYTOTOXIC THERAPYWHO ARE THEY AND WHAT IS THEIR UNMET NED?
    Agashe, V. R.
    Clapton, G.
    Shimshak, J.
    Rai, K.
    VALUE IN HEALTH, 2014, 17 (03) : A237 - A237
  • [38] Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia
    Dretzke, J.
    Barton, P.
    Kaambwa, B.
    Connock, M.
    Uthman, O.
    Bayliss, S.
    Meads, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 19 - 26
  • [39] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S282 - S283
  • [40] RESULTS OF PROSPECTIVE OBSERVATIONAL TRIAL OF POLISH ADULT LEUKEMIA GROUP (PALG) ON IBRUTINIB COMPASSIONATE USE IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN POLAND
    Iskierka-Jaidiewska, E.
    Hus, M.
    Giannopaulos, K.
    Madro, E.
    Holojda, J.
    Piotrowska, M.
    Zaucha, J. M.
    Piszczeklo, W.
    Szeremet, A.
    Wojciechowska, M.
    Steckiewicz, P.
    Knopinhska-Postuszny, W.
    Osowiecki, M.
    Drozd-Sokotowska, J.
    Kumiega, B.
    Kyrcz-Krzemien, S.
    Halka, J.
    Dudzinski, M.
    Wieszczy, P.
    Warzocha, K.
    Jamroziak, K.
    HAEMATOLOGICA, 2016, 101 : 439 - 440
12345